高级检索
当前位置: 首页 > 详情页

Holistic immunomodulation for small cell lung cancer

文献详情

资源类型:
Pubmed体系:
机构: [1]Cancer Center, Faculty of Health Science, University of Macau, Macau (SAR), China. MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau (SAR), China. Electronic address: lhleung@um.edu.mo. [2]Dr. Neher's Biophysics Laboratory for Innovative Drug Discovery, State Key Laboratory of Quality Research in Chinese Medicine, Macau Institute for Applied Research in Medicine and Health, Macau University of Science and Technology, Macau, SAR, China. [3]Cancer Center, Faculty of Health Science, University of Macau, Macau (SAR), China. MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau (SAR), China. [4]Zhuhai Hospital of Traditional Chinese and Western Medicine, Zhuhai City, Guangdong, P.R. China. [5]Department of Oncology, Kiang Wu Hospital, Macau (SAR), China. Electronic address: sumscaoyabing@hotmail.com.
出处:
ISSN:

关键词: SCLC Target CAR Therapeutic strategies TCM Immunotherapy

摘要:
Small cell lung cancer (SCLC) is characterized by a high mortality rate, rapid growth, and early metastasis, which lead to a poor prognosis. Moreover, limited clinical treatment options further lower the survival rate of patients. Therefore, novel technology and agents are urgently required to enhance clinical efficacy. In this review, from a holistic perspective, we summarized the therapeutic targets, agents and strategies with the most potential for treating SCLC, including chimeric antigen receptor (CAR) T therapy, immunomodulating antibodies, traditional Chinese medicines (TCMs), and the microbiota, which have been found recently to improve the clinical outcomes and prognosis of SCLC. Multiomics technologies can be integrated to develop effective diagnostic methods and identify new targets for new drug discovery in SCLC. We discussed in depth the feasibility, potential, and challenges of these new strategies, as well as their combinational treatments, which may provide promising alternatives for enhancing the clinical efficacy of SCLC in the future.Copyright © 2022. Published by Elsevier Ltd.

基金:
语种:
PubmedID:
中科院(CAS)分区:
出版当年[2021]版
大类 | 1 区 医学
小类 | 2 区 肿瘤学
最新[2025]版
大类 | 2 区 医学
小类 | 2 区 肿瘤学
第一作者:
第一作者机构: [1]Cancer Center, Faculty of Health Science, University of Macau, Macau (SAR), China. MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau (SAR), China. Electronic address: lhleung@um.edu.mo. [5]Department of Oncology, Kiang Wu Hospital, Macau (SAR), China. Electronic address: sumscaoyabing@hotmail.com. [*1]Cancer Center, Faculty of Health Sciences, University of Macau, Macao Special Administrative Region of China.
共同第一作者:
通讯作者:
通讯机构: [1]Cancer Center, Faculty of Health Science, University of Macau, Macau (SAR), China. MOE Frontiers Science Center for Precision Oncology, University of Macau, Macau (SAR), China. Electronic address: lhleung@um.edu.mo. [5]Department of Oncology, Kiang Wu Hospital, Macau (SAR), China. Electronic address: sumscaoyabing@hotmail.com. [*1]Cancer Center, Faculty of Health Sciences, University of Macau, Macao Special Administrative Region of China.
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:2018 今日访问量:0 总访问量:645 更新日期:2024-07-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 广东省中医院 技术支持:重庆聚合科技有限公司 地址:广州市越秀区大德路111号